

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

<https://marketpublishers.com/r/CC44EFF79B1EN.html>

Date: April 2020

Pages: 338

Price: US\$ 4,296.00 (Single User License)

ID: CC44EFF79B1EN

Abstracts

The global cancer biomarkers market was valued at \$10,944.08 million in 2019, and is projected to reach \$26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of

various industries such as healthcare and pharmaceuticals.

The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.

The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Profiling Technology

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics-based Tests

By Biomolecule

Genetic Biomarkers

Protein Biomarkers

Glyco-biomarkers

By Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

By Application

Diagnostics

Drug Discovery and Development

Prognostics

Risk Assessment

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Russia

Rest of Europe

Asia Pacific

Japan

China

India

Australia

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

United Arab Emirates

Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Bristol-Myers Squibb Compnay

Exact Sciences Corporation

F.Hoffmann-La Roche Ltd.

Merck KGaA

PerkinElmer, Inc.

Qiagen N.V.

Siemens AG

Thermo Fisher Scientific, Inc.

Contents

CHAPTER 1:INTRODUCTION40

- 1.1.Report description40
- 1.2.Key benefits for stakeholders41
- 1.3.Key market segments43
 - 1.3.1.List of key players profiled in the report45
- 1.4.Research methodology46
 - 1.4.1.Secondary research48
 - 1.4.2.Primary research48
 - 1.4.3.Analyst tools and models49

CHAPTER 2:EXECUTIVE SUMMARY50

- 2.1.Key findings of the study52
- 2.2.CXO perspective53

CHAPTER 3:MARKET OVERVIEW54

- 3.1.Market definition and scope54
- 3.2.Biomarker Diagnosis vs. Conventional Diagnosis56
- 3.3.Key findings57
 - 3.3.1.Top investment pockets57
- 3.4.Porter's five forces analysis59
 - 3.4.1.Bargaining power of buyers59
 - 3.4.2.Bargaining power of suppliers60
 - 3.4.3.Threat of new entrants61
 - 3.4.4.Threat of substitutes62
 - 3.4.5.Intensity of competitive rivalry63
- 3.5.Top player positioning, 201964
- 3.6.Market dynamics65
 - 3.6.1.Drivers65
 - 3.6.1.1.Rise in incidence and prevalence of various cancer types65
 - 3.6.1.2.Growth in importance of biological and targeted drug therapies67
 - 3.6.1.3.Increase in acquisitions and collaborations69
 - 3.6.1.4.Increase in technological advancements70
 - 3.6.1.5.High accuracy and reliability70
 - 3.6.1.6.Rise in investment from government, public, and private sectors70

- 3.6.1.7.Increase in clinical trials71
- 3.6.1.8.Growth in popularity of personalized medicine and companion diagnostics71
- 3.6.2.Restrict72
- 3.6.2.1.High cost of drug development and threat of failure72
- 3.6.2.2.Unregulated government regulation and reimbursement policies72
- 3.6.2.3.Adverse effects of cancer drug therapy73
- 3.6.3.Opportunity73
- 3.6.3.1.Advancement of cancer drugs research73
- 3.6.3.2.Increased focus towards advanced treatment protocols74
- 3.6.3.3.Significant unmet need in cancer diagnosis74
- 3.6.3.4.Increased awareness to reduce healthcare costs74
- 3.6.3.5.Opportunities in emerging economies75
- 3.6.4.Impact Analyses75
- 3.7.PATENT ANALYSIS76
- 3.8.Clinical Trials Analysis78

CHAPTER 4:CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY79

- 4.1.Overview79
 - 4.1.1.Market size and forecast, by profiling technologies80
- 4.2.OMIC TECHNOLOGIES82
 - 4.2.1.Key market trends and growth opportunities82
 - 4.2.2.Market size and forecast, by region83
 - 4.2.3.Market analysis, by country84
 - 4.2.4.Market size and forecast, by type85
 - 4.2.5.Genomics86
 - 4.2.5.1.Market Size and forecast87
 - 4.2.5.2.Next Generation Sequencing (NGS)88
 - 4.2.5.3.Microarray89
 - 4.2.5.4.Polymerase chain reaction (PCR)89
 - 4.2.6.Proteomics90
 - 4.2.6.1.Market size and forecast90
 - 4.2.6.2.Mass spectrometry92
 - 4.2.6.3.2D gel electrophoresis92
 - 4.2.6.4.Protein microarray technology93
 - 4.2.6.5.Antibody array technology94
 - 4.2.6.6.Peptide array technology94
 - 4.2.7.Other omic technologies95
 - 4.2.7.1.Market size and forecast95

4.2.7.2. Metabolomics	96
4.2.7.3. Glycomics	97
4.3. IMAGING TECHNOLOGIES	97
4.3.1. Key market trends and growth opportunities	97
4.3.2. Market size and forecast, by region	98
4.3.3. Market analysis, by countries	99
4.3.4. Market size and forecast, by type	100
4.3.5. Magnetic resonance imaging (MRI)	101
4.3.5.1. Market size and forecast	102
4.3.6. Positron emission tomography (PET)	103
4.3.6.1. Market size and forecast	103
4.3.7. Computed tomography (CT)	104
4.3.7.1. Market size and forecast	105
4.3.8. Mammography	105
4.3.8.1. Market size and forecast	106
4.3.9. Ultrasound	107
4.3.9.1. Market size and forecast	107
4.4. IMMUNOASSAYS	108
4.4.1. Key market trends and growth opportunities	109
4.4.2. Market size and forecast, by region	109
4.4.3. Market analysis, by country	110
4.4.4. Market size and forecast, by type	112
4.4.5. Immunohistochemistry (IHC) tests	113
4.4.5.1. Market size and forecast	113
4.4.6. Enzyme-linked immunosorbent assay (ELISA)	114
4.4.6.1. Market size and forecast	114
4.4.7. Flow cytometry	115
4.4.7.1. Market size and forecast	116
4.5. CYTOGENETICS-BASED TESTS	117
4.5.1. Key market trends and growth opportunities	117
4.5.2. Market size and forecast, by region	118
4.5.3. Market analysis, by country	119
4.5.4. Market size and forecast, by type	120
4.5.5. In-situ hybridization	121
4.5.5.1. Market size and forecast	121
4.5.6. Others	122
4.5.6.1. Market size and forecast	122

CHAPTER 5: CANCER BIOMARKERS MARKET, BY BIOMOLECULE 124

5.1.Overview124

5.1.1.Market size and forecast125

5.2.Genetic Biomarkers126

5.2.1.Market size and forecast, by region128

5.2.2.Market analysis, by country129

5.3.Protein Biomarkers130

5.3.1.Market size and forecast, by region130

5.3.2.Market analysis, by country131

5.4.Glyco-Biomarkers133

5.4.1.Market size and forecast, by region134

5.4.2.Market analysis, by country135@CHAPTER 6:CANCER BIOSENSORS

MARKET, BY CANCER TYPE136**6.1.Overview136**

6.1.1.Market size and forecast137

6.2.Breast Cancer138

6.2.1.Market size and forecast, by region139

6.2.2.Market analysis, by country140

6.3.Lung Cancer141

6.3.1.Market size and forecast, by region141

6.3.2.Market analysis, by country142

6.4.Colorectal cancer143

6.4.1.Market size and forecast, by region144

6.4.2.Market analysis, by country145

6.5.Prostate cancer146

6.5.1.Market size and forecast, by region147

6.5.2.Market analysis, by country148

6.6.Stomach cancer149

6.6.1.Market size and forecast, by region150

6.6.2.Market analysis, by country150

6.7.Others152

6.7.1.Market size and forecast, by region152

6.7.2.Market analysis, by country153

CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION155**7.1.Overview155**

7.1.1.Market size and forecast155

7.2.Diagnostics157

7.2.1.	Market size and forecast, by region	158
7.2.2.	Market analysis, by country	159
7.3.	Drug Discovery and Development	160
7.3.1.	Market size and forecast, by region	161
7.3.2.	Market analysis, by country	162
7.4.	Prognostics	163
7.4.1.	Market size and forecast, by region	164
7.4.2.	Market analysis, by country	164
7.5.	Risk Assessment	166
7.5.1.	Market size and forecast, by region	166
7.5.2.	Market analysis, by country	167
7.6.	Others	168
7.6.1.	Market size and forecast, by region	169
7.6.2.	Market analysis, by country	170

CHAPTER 8: CANCER BIOMARKERS MARKET, BY REGION 172

8.1.	Overview	172
8.1.1.	Market size and forecast	173
8.2.	North America	174
8.2.1.	Key market trends and opportunities	174
8.2.2.	Market analysis by country	175
8.2.2.1.	U.S.	176
8.2.2.1.1.	U.S. market size and forecast, by profiling technologies	176
8.2.2.1.2.	U.S. market size and forecast, by biomolecules	177
8.2.2.1.3.	U.S. market size and forecast, by cancer type	178
8.2.2.1.4.	U.S. market size and forecast, by application	179
8.2.2.2.	Canada	180
8.2.2.2.1.	Canada market size and forecast, by profiling technologies	180
8.2.2.2.2.	Canada market size and forecast, by biomolecules	182
8.2.2.2.3.	Canada market size and forecast, by cancer type	183
8.2.2.2.4.	Canada market size and forecast, by application	184
8.2.2.3.	Mexico	185
8.2.2.3.1.	Mexico market size and forecast, by profiling technologies	185
8.2.2.3.2.	Mexico market size and forecast, by biomolecules	187
8.2.2.3.3.	Mexico market size and forecast, by cancer type	188
8.2.2.3.4.	Mexico market size and forecast, by application	189
8.2.3.	North America market size and forecast, by profiling technologies	190
8.2.4.	North America market size and forecast, by biomolecules	191

8.2.5.North America market size and forecast, by cancer type	192
8.2.6.North America market size and forecast, by application	193
8.3.Europe	194
8.3.1.Key market trends and opportunities	194
8.3.2.Market analysis by country	195
8.3.2.1.Germany	197
8.3.2.1.1.Germany market size and forecast, by profiling technologies	197
8.3.2.1.2.Germany market size and forecast, by biomolecules	199
8.3.2.1.3.Germany market size and forecast, by cancer type	200
8.3.2.1.4.Germany market size and forecast, by application	201
8.3.2.2.France	202
8.3.2.2.1.France market size and forecast, by profiling technologies	202
8.3.2.2.2.France market size and forecast, by biomolecules	204
8.3.2.2.3.France market size and forecast, by cancer type	205
8.3.2.2.4.France market size and forecast, by application	206
8.3.2.3.UK	207
8.3.2.3.1.UK market size and forecast, by profiling technologies	207
8.3.2.3.2.UK market size and forecast, by biomolecules	208
8.3.2.3.3.UK market size and forecast, by cancer type	209
8.3.2.3.4.UK market size and forecast, by application	210
8.3.2.4.Italy	211
8.3.2.4.1.Italy market size and forecast, by profiling technologies	211
8.3.2.4.2.Italy market size and forecast, by biomolecules	212
8.3.2.4.3.Italy market size and forecast, by cancer type	213
8.3.2.4.4.Italy market size and forecast, by application	214
8.3.2.5.Russia	215
8.3.2.5.1.Russia market size and forecast, by profiling technologies	215
8.3.2.5.2.Russia market size and forecast, by biomolecules	217
8.3.2.5.3.Russia market size and forecast, by cancer type	218
8.3.2.5.4.Russia market size and forecast, by application	219
8.3.2.6.Rest of Europe	220
8.3.2.6.1.Rest of Europe market size and forecast, by profiling technologies	220
8.3.2.6.2.Rest of Europe market size and forecast, by biomolecules	222
8.3.2.6.3.Rest of Europe market size and forecast, by cancer type	223
8.3.2.6.4.Rest of Europe market size and forecast, by application	224
8.3.3.Europe market size and forecast, by profiling technologies	225
8.3.4.Europe market size and forecast, by biomolecules	226
8.3.5.Europe market size and forecast, by cancer type	227
8.3.6.Europe market size and forecast, by application	228

8.4.Asia-Pacific229

8.4.1.Key market trends and opportunities229

8.4.2.Market analysis by country230

8.4.2.1.Japan231

8.4.2.1.1.Japan market size and forecast, by profiling technologies231

8.4.2.1.2.Japan market size and forecast, by biomolecules233

8.4.2.1.3.Japan market size and forecast, by cancer type234

8.4.2.1.4.Japan market size and forecast, by application235

8.4.2.2.China236

8.4.2.2.1.China market size and forecast, by profiling technologies236

8.4.2.2.2.China market size and forecast, by biomolecules237

8.4.2.2.3.China market size and forecast, by cancer type238

8.4.2.2.4.China market size and forecast, by application239

8.4.2.3.Australia240

8.4.2.3.1.Australia market size and forecast, by profiling technologies240

8.4.2.3.2.Australia market size and forecast, by biomolecules242

8.4.2.3.3.Australia market size and forecast, by cancer type243

8.4.2.3.4.Australia market size and forecast, by application244

8.4.2.4.India245

8.4.2.4.1.India market size and forecast, by profiling technologies245

8.4.2.4.2.India market size and forecast, by biomolecules246

8.4.2.4.3.India market size and forecast, by cancer type247

8.4.2.4.4.India market size and forecast, by application248

8.4.2.5.Rest of Asia-Pacific249

8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies249

8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules250

8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type251

8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application252

8.4.3.Asia-Pacific market size and forecast, by profiling technologies253

8.4.4.Asia-Pacific market size and forecast, by biomolecules254

8.4.5.Asia-Pacific market size and forecast, by cancer type255

8.4.6.Asia-Pacific market size and forecast, by application256

8.5.LAMEA257

8.5.1.Key market trends and opportunities257

8.5.2.Market analysis by country258

8.5.2.1.Brazil260

8.5.2.1.1.Brazil market size and forecast, by profiling technologies260

8.5.2.1.2.Brazil market size and forecast, by biomolecules261

8.5.2.1.3.Brazil market size and forecast, by cancer type262

8.5.2.1.4.Brazil market size and forecast, by application	263
8.5.2.2.Saudi Arabia	264
8.5.2.2.1.Saudi Arabia market size and forecast, by profiling technologies	264
8.5.2.2.2.Saudi Arabia market size and forecast, by biomolecules	266
8.5.2.2.3.Saudi Arabia market size and forecast, by cancer type	267
8.5.2.2.4.Saudi Arabia market size and forecast, by application	268
8.5.2.3.United Arab Emirates	269
8.5.2.3.1.United Arab Emirates market size and forecast, by profiling technologies	269
8.5.2.3.2.United Arab Emirates market size and forecast, by biomolecules	270
8.5.2.3.3.United Arab Emirates market size and forecast, by cancer type	271
8.5.2.3.4.United Arab Emirates market size and forecast, by application	272
8.5.2.4.Rest of LAMEA	273
8.5.2.4.1.Rest of LAMEA market size and forecast, by profiling technologies	273
8.5.2.4.2.Rest of LAMEA market size and forecast, by biomolecules	275
8.5.2.4.3.Rest of LAMEA market size and forecast, by cancer type	276
8.5.2.4.4.Rest of LAMEA market size and forecast, by application	277
8.5.3.LAMEA market size and forecast, by profiling technologies	278
8.5.4.LAMEA market size and forecast, by biomolecules	279
8.5.5.LAMEA market size and forecast, by cancer type	280
8.5.6.LAMEA market size and forecast, by application	281

CHAPTER 9:COMPANY PROFILES282

9.1.Abbott Laboratories	282
9.1.1.Company overview	282
9.1.2.Company snapshot	282
9.1.3.Operating business segments	283
9.1.4.Product portfolio	283
9.1.5.Business performance	285
9.2.BIO-RAD LABORATORIES, INC.	287
9.2.1.Company overview	287
9.2.2.Company snapshot	288
9.2.3.Operating business segments	289
9.2.4.Product Portfolio	289
9.2.5.Business performance	290
9.3.Bristol-Myers Squibb Company	292
9.3.1.Company overview	292
9.3.2.Company snapshot	293

9.3.3.Operating business segments	293
9.3.4.Product portfolio	294
9.3.5.Business performance	294
9.3.6.Key strategic moves and developments	296
9.5.EXACT SCIENCES CORPORATION	297
9.5.1.Company overview	297
9.5.2.Company snapshot	297
9.5.3.Operating business segments	298
9.5.4.Product portfolio	298
9.5.5.Business performance	299
9.5.6.Key strategic moves and developments	299
9.6.F. HOFFMANN-LA ROCHE LTD.	301
9.6.1.Company overview	301
9.6.2.Company snapshot	301
9.6.3.Operating business segments	302
9.6.4.Product portfolio	303
9.6.5.Business performance	304
305	
9.6.6.Key strategic moves and developments	306
9.7.Merck KGaA	307
9.7.1.Company overview	307
9.7.2.Company snapshot	307
9.7.3.Operating business segments	308
9.7.4.Product portfolio	308
9.7.5.Business performance	309
9.7.6.Key strategic moves and developments	311
9.8.PERKINELMER, INC.	312
9.8.1.Company overview	312
9.8.2.Company snapshot	312
9.8.3.Operating business segments	313
9.8.4.Product portfolio	314
9.8.5.Business performance	315
9.8.6.Key strategic moves and developments	317
9.9.QIAGEN N.V.	318
9.9.1.Company overview	318
9.9.2.Company snapshot	318
9.9.3.Operating business segments	319
9.9.4.Product portfolio	320
9.9.5.Business performance	320

9.9.6.Key strategic moves and developments	322
9.10.Siemens AG	323
9.10.1.Company overview	323
9.10.2.Company snapshot	324
9.10.3.Operating business segments	324
9.10.4.Product portfolio	325
9.10.5.Business performance	326
9.11.THERMO FISHER SCIENTIFIC, INC.	328
9.11.1.Company overview	328
9.11.2.Company snapshot	328
9.11.3.Operating business segments	329
9.11.4.Product portfolio	331
9.11.5.Business performance	332
9.11.6.Key strategic moves and developments	334

List Of Tables

LIST OF TABLES

TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES60

TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019–2027 (\$MILLION)86

TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)89

TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)92

TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)93

TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)97

TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)101

TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)105

TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)107

TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)116

TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)118

TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)124

TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)127

TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019–2027 (\$MILLION)131

TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)134

TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)137

TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)140

TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE,

2019–2027 (\$MILLION)144

TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)146

TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)149

TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)151

TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)154

TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)157

TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)160

TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019–2027 (\$MILLION)163

TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)165

TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)169

TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)171

TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)174

TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)177

TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 (\$MILLION)180

TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 (\$MILLION)182

TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)183

TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)185

TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)186

TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)187

TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)188

TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)190

TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)191

TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)192

TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)193

TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)194

TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)195

TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)196

TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY
PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)197

TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)198

TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY
CANCER TYPE 2019–2027 (\$MILLION)199

TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)200

TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY
2019–2026 (\$MILLION)202

TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)204

TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)206

TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)207

TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)208

TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)209

TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)210

TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)211

TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION

2019–2027 (\$MILLION)212

TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)213

TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)214

TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)215

TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)216

TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)217

TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)218

TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)219

TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)220

TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)221

TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)222

TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)223

TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)224

TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)225

TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)226

TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)227

TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)228

TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)229

TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)230

TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)231

TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)232

TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
COUNTRY 2019–2026 (\$MILLION)235

TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)236

TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)237

TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE
2019–2027 (\$MILLION)238

TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)239

TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)240

TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)241

TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE
2019–2027 (\$MILLION)242

TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)243

TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)244

TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)245

TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)246

TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)247

TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)248

TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES
2019–2027 (\$MILLION)249

TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE
2019–2027 (\$MILLION)250

TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)251

TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)252

TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY

BIOMOLECULES 2019–2027 (\$MILLION)253

TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
CANCER TYPE 2019–2027 (\$MILLION)254

TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)255

TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)256

TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)257

TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
CANCER TYPE 2019–2027 (\$MILLION)258

TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)259

TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY
2019–2026 (\$MILLION)261

TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)263

TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)264

TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)265

TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)266

TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY
PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)267

TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)269

TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY
CANCER TYPE 2019–2027 (\$MILLION)270

TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)271

TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE,
BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)272

TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE,
BY BIOMOLECULES 2019–2027 (\$MILLION)273

TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE,
BY CANCER TYPE 2019–2027 (\$MILLION)274

TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE,
BY APPLICATION 2019–2027 (\$MILLION)275

TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY
PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)276

TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)278

TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY
CANCER TYPE 2019–2027 (\$MILLION)279

TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY
APPLICATION 2019–2027 (\$MILLION)280

TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING
TECHNOLOGIES 2019–2027 (\$MILLION)281

TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY
BIOMOLECULES 2019–2027 (\$MILLION)282

TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER
TYPE 2019–2027 (\$MILLION)283

TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION
2019–2027 (\$MILLION)284

TABLE 124.ABBOTT: COMPANY SNAPSHOT285

TABLE 125.ABBOTT: OPERATING SEGMENTS286

TABLE 126.ABBOTT: PRODUCT PORTFOLIO287

TABLE 127.BIO-RAD: COMPANY SNAPSHOT291

TABLE 128.BIO-RAD: OPERATING SEGMENTS292

TABLE 129.BIO-RAD: PRODUCT PORTFOLIO292

TABLE 130.BMS: COMPANY SNAPSHOT296

TABLE 131.BMS: PRODUCT PORTFOLIO297

TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT300

TABLE 133.EXACT SCIEN

I would like to order

Product name: Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

Product link: <https://marketpublishers.com/r/CC44EFF79B1EN.html>

Price: US\$ 4,296.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC44EFF79B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970